Developer docs
API playgroundTry for free, no card

Search company profiles

北京新领先医药科技发展有限公司

Full company profile

uuid004rw15

Namestring
北京新领先医药科技发展有限公司
Legal namestring
北京新领先医药科技发展有限公司
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Beijing Xinlingxian Pharmaceutical Technology Development Co., Ltd. (SSE: 600222), founded in 2005 and headquartered in Beijing's Zhongguancun Software Park, operates as a full-chain pharmaceutical CXO serving domestic and international pharmaceutical companies. The service portfolio spans three integrated pillars: pharmaceutical CMC R&D (covering API synthesis, excipient development, formulation development, and analytical testing), clinical CRO (operated through the Deep Blue Sea subsidiary since 2007), and MAH (Marketing Authorization Holder) services including a one-stop 'MAH Supermarket' marketplace offering approved drug dossiers and contract R&D. The company is led by Chairman 陶新华 (Tao Xinhua) with President 高世静 (Gao Shijing) overseeing group operations and the pediatric subsidiary.

Technical infrastructure includes six international-standard R&D platforms in Zhengzhou's Airport Biotech Park (compliant with FDA, EMA, and NMPA GMP standards), spanning drug screening, drug evaluation in a GLP/AAALAC/CNAS-certified animal facility, large-molecule pilot manufacturing, small-molecule CMC formulation, cell technology services, and clinical CRO. Specialized platforms include China's first domestically developed in vitro-in vivo correlation (IVIVR) platform for predicting drug absorption and improving bioequivalence (BE) pass rates, a five-center impurity research division, a transdermal drug delivery platform led by former PLA expert 颜耀东 (Yan Yaodong), a Hangzhou pediatric formulations institute, and a Chongqing advanced formulations institute using hot-melt extrusion and spray-drying technologies. Analytical capabilities include a 1,000 sqm ISO 9001-certified testing center equipped with ICP-MS, LC-MS/MS, GC-MS/MS, IC, DSC, IR, HPLC, and GC instruments.

The company operates a B2B enterprise sales model with project-based contracting, serving 500+ upstream and downstream pharmaceutical companies. Distribution is supported by a nationwide footprint spanning 14 Chinese cities (with Deep Blue Sea clinical operations in 20+ cities) and clinical partnerships with nearly 1,000 clinical research institutions and 600+ clinical hospitals covering 1,500+ hospital departments. The group fields a senior R&D management team of approximately 1,000 professionals and runs 50–100 BE studies and dozens of Class I innovative-drug projects annually. Cumulative outputs include 1,000+ pharmaceutical R&D projects, 2,000+ clinical research projects, 200+ patent applications (nearly 100 authorized), and instrument-vendor joint laboratories with Shimadzu and Thermo Fisher Scientific. The company was ranked #1 among Chinese pharmaceutical R&D enterprises in 2019 and recognized as a 2025–2026 top-50 pharmaceutical R&D enterprise and trustworthy pharmaceutical company.

Short descriptiontext

Beijing Xinlingxian Pharmaceutical (SSE: 600222) is a China-based full-chain pharmaceutical CXO offering CMC formulation, clinical CRO, and MAH regulatory services to domestic and international pharmaceutical companies via 14 nationwide offices and specialized research institutes.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices14 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical CRO services, clinical research services, pharmaceutical CMC development, CDMO manufacturing services, MAH regulatory services
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Research and Development Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1CMC Pharmaceutical R&D Services
TypeProfessional Services
Description

Provides comprehensive pharmaceutical CMC (Chemistry, Manufacturing, and Controls) R&D services including raw material, excipient, formulation development, and analytical testing. Revenue generated through project-based service contracts.

leadingpharm.com
2Clinical CRO Services
TypeProfessional Services
Description

Clinical research organization services including Phase I-IV clinical trials, bioequivalence studies, PK/PD research, and medical affairs. Provided through subsidiary Deep Blue Sea.

leadingpharm.com
3MAH Services
TypeProfessional Services
Description

Marketing Authorization Holder services including project filing, regulatory affairs, and quality management. Also operates 'MAH Supermarket' offering product approvals and commissioned R&D.

leadingpharm.com
4CDMO Manufacturing
TypeManaged Services
Description

Contract development and manufacturing organization services through six international-standard platforms in Zhengzhou Airport Bio-industrial Park.

leadingpharm.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1新领先CXO·深蓝海
Description

临床CRO子品牌,提供I-III期临床研究、生物等效性研究、上市后研究、第三方稽查、IND和NDA申报及医学事务等服务,涵盖生物药、化药、中药、医疗器械、细胞与基因治疗等领域。

leadingpharm.com
+2 more records
Core offering1 text field

Beijing Xinlingxian (stock code 600222) provides full-industry-chain pharmaceutical R&D services covering pharmaceutical CMC R&D (API synthesis, formulation development, analytical testing, IVIVR modeling), clinical CRO (Phase I-IV trials, bioequivalence studies, PK/PD research), MAH (Marketing Authorization Holder) services, and CDMO manufacturing through six international-standard (FDA, EMA, NMPA GMP) platforms for domestic and international pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 90% one-time bioequivalence pass rate for BE studies
+2 more records
Product overview1 text field

北京新领先医药科技发展有限公司 (股票代码600222) operates a unified CXO (Contract X Organization) full-industry-chain service platform for pharmaceutical R&D. The portfolio consists of three core integrated service pillars: (1) 研发CMC平台 — covering API synthesis, excipient R&D, formulation development, analytical testing, and in vivo/in vitro correlation; (2) 临床CRO — a nationwide clinical research operations network providing Phase I–IV trials, bioequivalence, PK/PD, IIT, medical affairs, and third-party audits; and (3) MAH服务 — covering project initiation, regulatory affairs, and quality management for marketing authorization holders. These are supported by specialized research institutes (郑州液体制剂一致性评价中心, 北京药学研究院, 重庆高端制剂研究院, 杭州高端儿科研究院, 透皮给药制剂平台) and specialist platforms (体内外桥接IVIVR平台, 杂质研究事业部, 分析测试中心). The company operates sub-brands including 深蓝海生物医药 and 郑州深蓝海生物医药 for clinical CRO, and offers the MAH超市 as a one-stop product dossier marketplace. All platforms are coordinated under the 新领先CXO brand with shared quality management systems (ISO9001) and international GMP compliance (FDA, EMA, NMPA).

Product and service3 records
1Pharmaceutical CMC R&D Platform (药学CMC研发平台)
CategoryPharmaceutical CMC R&D
Description

Full drug development lifecycle services including API synthesis, excipient R&D, formulation development (generic drugs, improved new drugs, innovative drugs), analytical testing, in vivo/in vitro correlation, and regulatory registration for pharmaceutical companies.

2Clinical CRO Services (临床CRO)
CategoryClinical Research
Description

Full-service clinical research organization providing Phase I-IV clinical trials, bioequivalence (BE) studies, PK/PD research, IIT studies, medical affairs, third-party audits, and post-marketing surveillance for pharmaceutical sponsors across China.

3MAH Services (MAH服务)
CategoryRegulatory and MAH Services
Description

Marketing Authorization Holder (MAH) services covering project initiation, regulatory affairs consulting, full life-cycle quality management, and one-stop MAH Supermarket (MAH超市) platform offering approved drug dossiers, contract R&D, and clinical research services.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Deep Blue Sea Biological Medicine (深蓝海生物医药)
Strategic tierCoreTypeOthers
Description

Deep Blue Sea is a subsidiary brand of Xinlingxian in clinical CRO, established in 2007. It provides comprehensive clinical research services including Phase I-III clinical trials, bioequivalence studies, post-market research, and regulatory affairs. Has conducted 2000+ clinical research projects and partners with nearly 1000 clinical institutions.

leadingpharm.com
2Huludao Pharmaceutical (葫芦娃药业)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Co-founded Hangzhou Kanglingxian with Huludao Pharmaceutical in 2022 to focus on high-end pediatric formulation R&D. Kanglingxian has developed nearly 60-person R&D team and 30+ products in development, with nearly 10 receiving clinical approval.

leadingpharm.com
3Shanghai HaoYuan Pharmaceutical (上海皓元医药)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Strategic partner in the 'Four-Party Co-construction' academic-industry collaboration initiative with Beijing Normal University Chemistry Department and Lanzhou University Chemistry College for joint research and talent development.

leadingpharm.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner in four-party collaboration for joint research exchange,产学研 cooperation, and scientific achievement translation. BNU professor shared research progress on radiopharmaceuticals for Alzheimer's detection and cancer fluorescent probe drug development.

5Lanzhou University Chemistry and Chemical Engineering College (兰州大学化学化工学院)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic partner in four-party collaboration. Lanzhou University is home to National Key Laboratory of Functional Organic Molecules. The collaboration focuses on joint research, talent cultivation, and promoting industry-academia-research cooperation.

leadingpharm.com
6Shenyang Pharmaceutical University (沈阳药科大学)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partner in pharmaceutical advanced professional training program. The first cohort of the jointly-run pharmaceutical advanced professional training class successfully concluded. Coursework covers pharmaceutical chemistry, pharmacology, pharmaceutics, pharmaceutical analysis, and frontier topics like green chemistry and pharmacokinetics.

leadingpharm.com
7Beijing Medical University Third Hospital (北医三院)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Clinical research partner for Kanglingxian's pediatric drug development. Kanglingxian plans to establish multi-dimensional cooperation with renowned medical institutions including BUMC for pediatric clinical needs.

leadingpharm.com
8CMAC Center Imaging IRC Alliance (CMAC中心影像IRC联盟)
Strategic tierMinorTypeOthers
Description

Industry alliance for independent imaging review in clinical trials. Xinlingxian's VP Zhang Ronghuo was appointed as expert committee member of the inaugural IRC alliance, contributing to standardization of independent imaging assessment in clinical research.

leadingpharm.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
1JOINN Laboratories
TypeDirect peer
Description

China-based preclinical and clinical CRO with GLP-certified facilities for safety evaluation and bioanalytical services. Comparable for preclinical CMC support and safety pharmacology work that underpins CMC submissions.

TypeDirect peer
Description

Integrated drug discovery, development, and manufacturing services company with CMC, preclinical, clinical, and API manufacturing capabilities across China, US, and UK. Directly comparable as an integrated CRO/CDMO with similar full-chain service positioning.

TypeDirect peer
Description

Small-molecule API and drug product CDMO arm of WuXi AppTec, the global leader in this segment. Direct competitor for Xinlingxian's small-molecule CMC formulation research and integrated CDMO offerings.

TypeDirect peer
Description

China's leading clinical CRO with strong Phase I-IV capabilities and expanding into data sciences and biostatistics. Highly comparable through Deep Blue Sea, which competes directly with Tigermed for clinical trial projects and BE studies in China.

TypeDirect peer
Description

Chemistry-focused CRO/CDMO providing custom synthesis, building blocks, and process R&D for pharmaceutical companies. Comparable as a chemistry and small-molecule services peer, particularly relevant for API development and impurity research work.

TypeDirect peer
Description

Largest integrated CRO/CDMO in China and globally, offering laboratory testing, CMC, clinical CRO, and CDMO services across small and large molecules. Directly comparable as an integrated CXO platform serving similar pharmaceutical clients; the benchmark competitor that Xinlingxian must differentiate against.

7Porton Pharma
TypeDirect peer
Description

Chinese CDMO providing small molecule API and formulation CDMO services plus peptide and oligonucleotide capabilities. Comparable as a small-molecule drug product CDMO competitor, particularly relevant given Xinlingxian's CDMO manufacturing platform in Zhengzhou.

TypeDirect peer
Description

Preclinical CRO offering drug discovery, IND-enabling toxicology, and CMC services with both China and US operations. Comparable as a preclinical and early development CRO supporting pharmaceutical R&D programs from discovery through CMC.

TypeEmerging player
Description

Biologics CDMO and cell/gene therapy services arm of Genscript, focused on plasmid, viral vector, and cell therapy CMC/manufacturing. Emerging peer for Xinlingxian's biologics and large-molecule pilot/scale-up capabilities in Zhengzhou.

10Asymchem Laboratories
TypeDirect peer
Description

Leading Chinese CDMO specializing in small molecule API and intermediate development/manufacturing with strong international client base. Comparable as a CMC and manufacturing services competitor, particularly for small-molecule formulation and API CDMO work.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers9 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance5 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

北京新领先医药科技发展有限公司

Pharmaceutical Contract Research and Development Servicesleadingpharm.com

Beijing Xinlingxian Pharmaceutical (SSE: 600222) is a China-based full-chain pharmaceutical CXO offering CMC formulation, clinical CRO, and MAH regulatory services to domestic and international pharmaceutical companies via 14 nationwide offices and specialized research institutes.

What 北京新领先医药科技发展有限公司 does

Beijing Xinlingxian Pharmaceutical Technology Development Co., Ltd. (SSE: 600222), founded in 2005 and headquartered in Beijing's Zhongguancun Software Park, operates as a full-chain pharmaceutical CXO serving domestic and international pharmaceutical companies. The service portfolio spans three integrated pillars: pharmaceutical CMC R&D (covering API synthesis, excipient development, formulation development, and analytical testing), clinical CRO (operated through the Deep Blue Sea subsidiary since 2007), and MAH (Marketing Authorization Holder) services including a one-stop 'MAH Supermarket' marketplace offering approved drug dossiers and contract R&D. The company is led by Chairman 陶新华 (Tao Xinhua) with President 高世静 (Gao Shijing) overseeing group operations and the pediatric subsidiary.

Technical infrastructure includes six international-standard R&D platforms in Zhengzhou's Airport Biotech Park (compliant with FDA, EMA, and NMPA GMP standards), spanning drug screening, drug evaluation in a GLP/AAALAC/CNAS-certified animal facility, large-molecule pilot manufacturing, small-molecule CMC formulation, cell technology services, and clinical CRO. Specialized platforms include China's first domestically developed in vitro-in vivo correlation (IVIVR) platform for predicting drug absorption and improving bioequivalence (BE) pass rates, a five-center impurity research division, a transdermal drug delivery platform led by former PLA expert 颜耀东 (Yan Yaodong), a Hangzhou pediatric formulations institute, and a Chongqing advanced formulations institute using hot-melt extrusion and spray-drying technologies. Analytical capabilities include a 1,000 sqm ISO 9001-certified testing center equipped with ICP-MS, LC-MS/MS, GC-MS/MS, IC, DSC, IR, HPLC, and GC instruments.

The company operates a B2B enterprise sales model with project-based contracting, serving 500+ upstream and downstream pharmaceutical companies. Distribution is supported by a nationwide footprint spanning 14 Chinese cities (with Deep Blue Sea clinical operations in 20+ cities) and clinical partnerships with nearly 1,000 clinical research institutions and 600+ clinical hospitals covering 1,500+ hospital departments. The group fields a senior R&D management team of approximately 1,000 professionals and runs 50–100 BE studies and dozens of Class I innovative-drug projects annually. Cumulative outputs include 1,000+ pharmaceutical R&D projects, 2,000+ clinical research projects, 200+ patent applications (nearly 100 authorized), and instrument-vendor joint laboratories with Shimadzu and Thermo Fisher Scientific. The company was ranked #1 among Chinese pharmaceutical R&D enterprises in 2019 and recognized as a 2025–2026 top-50 pharmaceutical R&D enterprise and trustworthy pharmaceutical company.

北京新领先医药科技发展有限公司 firmographics

Firmographics
Name
北京新领先医药科技发展有限公司
Legal name
北京新领先医药科技发展有限公司
Website
https://leadingpharm.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
51–100 employees
Short description
Beijing Xinlingxian Pharmaceutical (SSE: 600222) is a China-based full-chain pharmaceutical CXO offering CMC formulation, clinical CRO, and MAH regulatory services to domestic and international pharmaceutical companies via 14 nationwide offices and specialized research institutes.
Ownership category
akta.pro rank

北京新领先医药科技发展有限公司 industry classification

Industry
Product category
Pharmaceutical Contract Research and Development Services
NAICS
Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Pharmaceutical CRO services
  • Clinical research services
  • Pharmaceutical CMC development
  • CDMO manufacturing services
  • MAH regulatory services

Where 北京新领先医药科技发展有限公司 is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices14 records

Markets served

北京新领先医药科技发展有限公司 business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CMC Pharmaceutical R&D Services: Provides comprehensive pharmaceutical CMC (Chemistry, Manufacturing, and Controls) R&D services including raw material, excipient, formulation development, and analytical testing. Revenue generated through project-based service contracts.
  2. Clinical CRO Services: Clinical research organization services including Phase I-IV clinical trials, bioequivalence studies, PK/PD research, and medical affairs. Provided through subsidiary Deep Blue Sea.
  3. MAH Services: Marketing Authorization Holder services including project filing, regulatory affairs, and quality management. Also operates 'MAH Supermarket' offering product approvals and commissioned R&D.
  4. CDMO Manufacturing: Contract development and manufacturing organization services through six international-standard platforms in Zhengzhou Airport Bio-industrial Park.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

北京新领先医药科技发展有限公司 product offering

Product offering

Core offering

Beijing Xinlingxian (stock code 600222) provides full-industry-chain pharmaceutical R&D services covering pharmaceutical CMC R&D (API synthesis, formulation development, analytical testing, IVIVR modeling), clinical CRO (Phase I-IV trials, bioequivalence studies, PK/PD research), MAH (Marketing Authorization Holder) services, and CDMO manufacturing through six international-standard (FDA, EMA, NMPA GMP) platforms for domestic and international pharmaceutical companies.

Product overview

北京新领先医药科技发展有限公司 (股票代码600222) operates a unified CXO (Contract X Organization) full-industry-chain service platform for pharmaceutical R&D. The portfolio consists of three core integrated service pillars: (1) 研发CMC平台 — covering API synthesis, excipient R&D, formulation development, analytical testing, and in vivo/in vitro correlation; (2) 临床CRO — a nationwide clinical research operations network providing Phase I–IV trials, bioequivalence, PK/PD, IIT, medical affairs, and third-party audits; and (3) MAH服务 — covering project initiation, regulatory affairs, and quality management for marketing authorization holders. These are supported by specialized research institutes (郑州液体制剂一致性评价中心, 北京药学研究院, 重庆高端制剂研究院, 杭州高端儿科研究院, 透皮给药制剂平台) and specialist platforms (体内外桥接IVIVR平台, 杂质研究事业部, 分析测试中心). The company operates sub-brands including 深蓝海生物医药 and 郑州深蓝海生物医药 for clinical CRO, and offers the MAH超市 as a one-stop product dossier marketplace. All platforms are coordinated under the 新领先CXO brand with shared quality management systems (ISO9001) and international GMP compliance (FDA, EMA, NMPA).

Differentiator

Problem solved

Functional benefit

Brands

  • 新领先CXO·深蓝海: 临床CRO子品牌,提供I-III期临床研究、生物等效性研究、上市后研究、第三方稽查、IND和NDA申报及医学事务等服务,涵盖生物药、化药、中药、医疗器械、细胞与基因治疗等领域。
  • 郑州深蓝海生物医药
  • 杭州康领先医药

Products and services

  • Pharmaceutical CMC R&D Platform (药学CMC研发平台) Full drug development lifecycle services including API synthesis, excipient R&D, formulation development (generic drugs, improved new drugs, innovative drugs), analytical testing, in vivo/in vitro correlation, and regulatory registration for pharmaceutical companies.
  • Clinical CRO Services (临床CRO) Full-service clinical research organization providing Phase I-IV clinical trials, bioequivalence (BE) studies, PK/PD research, IIT studies, medical affairs, third-party audits, and post-marketing surveillance for pharmaceutical sponsors across China.
  • MAH Services (MAH服务) Marketing Authorization Holder (MAH) services covering project initiation, regulatory affairs consulting, full life-cycle quality management, and one-stop MAH Supermarket (MAH超市) platform offering approved drug dossiers, contract R&D, and clinical research services.

Quantifiable outcome

  • Over 90% one-time bioequivalence pass rate for BE studies
  • +2 more outcomes

Companies that use 北京新领先医药科技发展有限公司

Customer profile

Named customers9 records

Segments1 record

Ideal customer profiles1 record

北京新领先医药科技发展有限公司 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

北京新领先医药科技发展有限公司 partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered core and minor.

  • Deep Blue Sea Biological Medicine (深蓝海生物医药)coreOthersDeep Blue Sea is a subsidiary brand of Xinlingxian in clinical CRO, established in 2007. It provides comprehensive clinical research services including Phase I-III clinical trials, bioequivalence studies, post-market research, and regulatory affairs. Has conducted 2000+ clinical research projects and partners with nearly 1000 clinical institutions.
  • Huludao Pharmaceutical (葫芦娃药业)coreStrategic or Co-development PartnerCo-founded Hangzhou Kanglingxian with Huludao Pharmaceutical in 2022 to focus on high-end pediatric formulation R&D. Kanglingxian has developed nearly 60-person R&D team and 30+ products in development, with nearly 10 receiving clinical approval.
  • Shanghai HaoYuan Pharmaceutical (上海皓元医药)minorStrategic or Co-development PartnerStrategic partner in the 'Four-Party Co-construction' academic-industry collaboration initiative with Beijing Normal University Chemistry Department and Lanzhou University Chemistry College for joint research and talent development.
  • Beijing Normal University Chemistry College (北京师范大学化学学院)minorStrategic or Co-development PartnerAcademic partner in four-party collaboration for joint research exchange,产学研 cooperation, and scientific achievement translation. BNU professor shared research progress on radiopharmaceuticals for Alzheimer's detection and cancer fluorescent probe drug development.
  • Lanzhou University Chemistry and Chemical Engineering College (兰州大学化学化工学院)minorStrategic or Co-development PartnerAcademic partner in four-party collaboration. Lanzhou University is home to National Key Laboratory of Functional Organic Molecules. The collaboration focuses on joint research, talent cultivation, and promoting industry-academia-research cooperation.
  • Shenyang Pharmaceutical University (沈阳药科大学)minorStrategic or Co-development PartnerPartner in pharmaceutical advanced professional training program. The first cohort of the jointly-run pharmaceutical advanced professional training class successfully concluded. Coursework covers pharmaceutical chemistry, pharmacology, pharmaceutics, pharmaceutical analysis, and frontier topics like green chemistry and pharmacokinetics.
  • Beijing Medical University Third Hospital (北医三院)minorStrategic or Co-development PartnerClinical research partner for Kanglingxian's pediatric drug development. Kanglingxian plans to establish multi-dimensional cooperation with renowned medical institutions including BUMC for pediatric clinical needs.
  • CMAC Center Imaging IRC Alliance (CMAC中心影像IRC联盟)minorOthersIndustry alliance for independent imaging review in clinical trials. Xinlingxian's VP Zhang Ronghuo was appointed as expert committee member of the inaugural IRC alliance, contributing to standardization of independent imaging assessment in clinical research.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

北京新领先医药科技发展有限公司 competitors and assessment

Company assessment

Direct peers

  • JOINN Laboratories: China-based preclinical and clinical CRO with GLP-certified facilities for safety evaluation and bioanalytical services. Comparable for preclinical CMC support and safety pharmacology work that underpins CMC submissions.
  • Pharmaron: Integrated drug discovery, development, and manufacturing services company with CMC, preclinical, clinical, and API manufacturing capabilities across China, US, and UK. Directly comparable as an integrated CRO/CDMO with similar full-chain service positioning.
  • WuXi STA (WuXi AppTec Subsidiary): Small-molecule API and drug product CDMO arm of WuXi AppTec, the global leader in this segment. Direct competitor for Xinlingxian's small-molecule CMC formulation research and integrated CDMO offerings.
  • Hangzhou Tigermed: China's leading clinical CRO with strong Phase I-IV capabilities and expanding into data sciences and biostatistics. Highly comparable through Deep Blue Sea, which competes directly with Tigermed for clinical trial projects and BE studies in China.
  • Pharmablock Sciences: Chemistry-focused CRO/CDMO providing custom synthesis, building blocks, and process R&D for pharmaceutical companies. Comparable as a chemistry and small-molecule services peer, particularly relevant for API development and impurity research work.
  • WuXi AppTec: Largest integrated CRO/CDMO in China and globally, offering laboratory testing, CMC, clinical CRO, and CDMO services across small and large molecules. Directly comparable as an integrated CXO platform serving similar pharmaceutical clients; the benchmark competitor that Xinlingxian must differentiate against.
  • Porton Pharma: Chinese CDMO providing small molecule API and formulation CDMO services plus peptide and oligonucleotide capabilities. Comparable as a small-molecule drug product CDMO competitor, particularly relevant given Xinlingxian's CDMO manufacturing platform in Zhengzhou.
  • Shanghai Medicilon: Preclinical CRO offering drug discovery, IND-enabling toxicology, and CMC services with both China and US operations. Comparable as a preclinical and early development CRO supporting pharmaceutical R&D programs from discovery through CMC.
  • Asymchem Laboratories: Leading Chinese CDMO specializing in small molecule API and intermediate development/manufacturing with strong international client base. Comparable as a CMC and manufacturing services competitor, particularly for small-molecule formulation and API CDMO work.

Emerging players

  • Genscript ProBio: Biologics CDMO and cell/gene therapy services arm of Genscript, focused on plasmid, viral vector, and cell therapy CMC/manufacturing. Emerging peer for Xinlingxian's biologics and large-molecule pilot/scale-up capabilities in Zhengzhou.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

北京新领先医药科技发展有限公司 social profiles

Digital presence

北京新领先医药科技发展有限公司 compliance and trust

Trust signal

Compliance5 records

北京新领先医药科技发展有限公司 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

北京新领先医药科技发展有限公司 leadership team

Management profile

Number of profiles

Profiles8 records

北京新领先医药科技发展有限公司 subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

北京新领先医药科技发展有限公司 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

北京新领先医药科技发展有限公司 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 北京新领先医药科技发展有限公司

What does 北京新领先医药科技发展有限公司 do?

Beijing Xinlingxian (stock code 600222) provides full-industry-chain pharmaceutical R&D services covering pharmaceutical CMC R&D (API synthesis, formulation development, analytical testing, IVIVR modeling), clinical CRO (Phase I-IV trials, bioequivalence studies, PK/PD research), MAH (Marketing Authorization Holder) services, and CDMO manufacturing through six international-standard (FDA, EMA, NMPA GMP) platforms for domestic and international pharmaceutical companies.

Is 北京新领先医药科技发展有限公司 a public or private company?

北京新领先医药科技发展有限公司 is a public company. It is classified as public and is currently operating.

When was 北京新领先医药科技发展有限公司 founded?

北京新领先医药科技发展有限公司 was founded in 2005. It employs 51 to 100 people.

Where is 北京新领先医药科技发展有限公司 based?

北京新领先医药科技发展有限公司 is headquartered in Beijing, China, in the Asia region.

How does 北京新领先医药科技发展有限公司 make money?

Four revenue lines are on record. CMC Pharmaceutical R&D Services are the primary driver. The others are clinical CRO Services, MAH Services and CDMO Manufacturing.

Who are 北京新领先医药科技发展有限公司's main competitors?

Direct peers on record are JOINN Laboratories, Pharmaron, WuXi STA (WuXi AppTec Subsidiary), Hangzhou Tigermed, Pharmablock Sciences, WuXi AppTec, Porton Pharma, Shanghai Medicilon and Asymchem Laboratories. Genscript ProBio is listed as an emerging player.

Does 北京新领先医药科技发展有限公司 have an API?

No public API is recorded for 北京新领先医药科技发展有限公司.

What industry is 北京新领先医药科技发展有限公司 in?

北京新领先医药科技发展有限公司's product category is Pharmaceutical Contract Research and Development Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales